scholarly journals Association of Isoprostanes-Related Oxidative Stress with Vulnerability of Culprit Lesions in Diabetic Patients with Acute Coronary Syndrome

2019 ◽  
Vol 60 (2) ◽  
pp. 271-279 ◽  
Author(s):  
Gong Su ◽  
Tao Zhang ◽  
Hong-Xia Yang ◽  
Wen-Long Dai ◽  
Tao Wang ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Acute Coronary Syndrome ◽  
Diabetic Patients ◽  
Coronary Syndrome

scholarly journals Glycemic Variation in Patients of Acute Coronary Syndrome with Hyperglycaemia and its Relationship with Oxidative Stress: A Pilot Study

2020 ◽  
Vol 07 (03) ◽  
pp. 16-19
Author(s):  
Kuldeep Kumar ◽  
Keyword(s):  
Oxidative Stress ◽  
Acute Coronary Syndrome ◽  
Glucose Tolerance ◽  
Glycemic Variability ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Diabetic Patients ◽  
Glycemic Status ◽  
Coronary Syndrome ◽  
The Relationship

Aim:The aim of this study was to establish the relationship between the glycemic variation in patients of Acute Coronary Syndrome (ACS) with hyperglycemia, oxidative stress and pre-discharge assessment of glycemic status by Oral Glucose Tolerance Test (OGTT). Materials and Method: Nineteen non-diabetic patients who presented with acute coronary syndrome with random blood sugar ≥200 mg/dl were recruited and glycemic variation was measured using CGMS followed by measurement of 8-isoprostanes PG-2alpha as a marker of oxidative stress, and pre-discharge OGTT was done to know the glycemic status at the time of discharge. Result: Mean MAGE (A parameter of glycemic variation) was 106.92±22.66 and mean 8-isoprostanes level was 206.05±179.57. There was no relationship between these two values. On doing OGTT, out of 19 non diabetic patients 11 turned out to be frank diabetic and 8 were having impaired glucose tolerance after OGTT, none were euglycemic. Conclusion:The study highlighted the issue of hyperglycaemia in ACS patients and their abnormal glucose tolerance in the short term, most of them turning to be frankly diabetic and being totally asymptomatic till the time of index event, although no correlation was found between glycemic variability and oxidative stress.

scholarly journals Lipidomic Analysis to Assess Oxidative Stress in Acute Coronary Syndrome and Acute Stroke Patients

Metabolites ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 412
Author(s):  
Martin Malý ◽  
Martin Hajšl ◽  
Kamila Bechyňská ◽  
Ondřej Kučerka ◽  
Martin Šrámek ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Acute Coronary Syndrome ◽  
High Performance ◽  
Coronary Syndrome ◽  
Lipidomic Analysis ◽  
Comprehensive Information ◽  
Group A ◽  
Fatty Acyls ◽  
Group D ◽  
Standard Marker

Alterations in lipid metabolism mediated by oxidative stress play a key role in the process of atherosclerosis and superimposed thrombosis; these can lead to acute coronary syndrome (ACS) and acute ischemic stroke (AIS). Multiple studies have shown that the formation of atheromatous lesions is initiated by oxidation of low-density lipoproteins incorporated into the intima of the vessel wall. Here, we studied lipids in plasma samples from three cohorts: 61 patients with ACS (group A), 49 patients with AIS (group D), and 82 controls (group K). Untargeted lipidomics based on high-performance liquid chromatography coupled to mass spectrometry (UHPLC-HRMS) was employed to obtain comprehensive information on whether relationships exist between these patient categories based on lipid patterns. In addition, malondialdehyde (MDA) as a standard marker of oxidative stress was monitored. The most characteristic lipids in group K were fatty acyls of hydroxyfatty acids (FAHFAs). As expected, MDA concentrations were the lowest in group K. Our findings can better explain ongoing pathologies, both acute and chronic, with the potential for future diagnosis and treatment.

Red wine reduces oxidative stress in patients with acute coronary syndrome

2005 ◽  
Vol 104 (1) ◽  
pp. 35-38 ◽  
Author(s):  
Eduardo Guarda ◽  
Iván Godoy ◽  
Rocío Foncea ◽  
Druso D. Pérez ◽  
Carlos Romero ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Acute Coronary Syndrome ◽  
Red Wine ◽  
Coronary Syndrome

scholarly journals Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome

2016 ◽  
Vol 23 (8) ◽  
pp. 922-931 ◽  
Author(s):  
Ryo Naito ◽  
Katsumi Miyauchi ◽  
Hiroyuki Daida ◽  
Takeshi Morimoto ◽  
Takafumi Hiro ◽  
...  
Keyword(s):  
Risk Management ◽  
Acute Coronary Syndrome ◽  
Coronary Plaque ◽  
Diabetic Patients ◽  
Total Risk ◽  
Coronary Syndrome ◽  
Plaque Regression

scholarly journals The Threshold of Admission Glycemia as a Predictor of Adverse Events in Diabetic and Non-Diabetic Patients with Acute Coronary Syndrome

2009 ◽  
Vol 3 ◽  
pp. CMC.S2289 ◽  
Author(s):  
Taysir S. Garadah ◽  
Salah Kassab ◽  
Qasim M. Al-Shboul ◽  
Abdulhai Alawadi
Keyword(s):  
Acute Coronary Syndrome ◽  
Adverse Events ◽  
Diabetic Patients ◽  
Stress Hyperglycemia ◽  
Coronary Syndrome ◽  
History Of ◽  
Group 3 ◽  
Group 2 ◽  
High Level ◽  
Group 1

Recent studies indicated a high prevalence of hyperglycemia in non-diabetic patients presenting with acute coronary syndrome (ACS). However, the threshold of admission glucose (AG) as a predictor of adverse events in ACS is unclear. Objective The aim of this study was to assess the threshold of admission glucose (AG) as a predictor of adverse events including Major Acute Cardiac Events (MACE) and mortality, during the first week of admitting patients presenting with ACS. Material and Methods The data of 551 patients with ACS were extracted and evaluated. Patients were stratified according to their blood glucose on admission into three groups: group 1: <7 mmol/L (n = 200, 36.3%) and group 2: >7 mmol/L and <15 mmol/L (n = 178, 32.3%) and group 3: ≥15 mmol/L (n = 173, 31.4%). Stress hyperglycemia was arbitrarily defined as AG levels > 7 mmol/L (group 2 and 3). Patients with ACS were sub-divided into two groups: patients with unstable angina (UA, n = 285) and those with ST segment elevation myocardial Infarction (STEMI, n = 266) and data were analyzed separately using multiple regression analysis. Results The mean age of patients was 59.7 ± 14.8 years and 63% were males. The overall mortality in the population was 8.5% (5.4% in STEMI and 3.1% in UA) patients. In STEMI patients, the odds ratio of stress hyperglycemia as predictor of mortality in group 3 compared with group 1 was 3.3 (CI 0.99-10.98, P < 0.05), while in group 2 compared with group 1 was 2.4 (CI: 0.75-8.07, P = 0.065) after adjustment for age and sex. Similarly, in UA patients, the odds ratio of stress hyperglycemia in group 3 compared with group 1 was 2.7 (CI 0.37-18.98, P < 0.05), while in group 2 compared with group 1 was 2.4 (CI: 0.4-15.2, P = 0.344) after adjustment for age and sex. The incidence of more than 2 MACE in both STEMI and UA patients was higher in group 3 compared with the other two groups. Regression analysis showed that history of DM, high level of LDL cholesterol, high level of HbA1c, and anterior infarction were significant predictors of adverse events while other risk factors such as BMI, history of hypertension and smoking were of no significance. Conclusion This study indicates that the stress hyperglycemia on admission is a powerful predictor of increased major adverse events and hospital mortality in patients with acute coronary syndrome.

scholarly journals Safety and efficacy of bivalirudin in diabetic acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
A Golam Mostofa ◽  
T Parvin ◽  
R Masum Mandal ◽  
S Ali Ahsan ◽  
R Afrin
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Major Bleeding ◽  
Guide Wire ◽  
Coronary Intervention ◽  
Diabetic Patients ◽  
Safety And Efficacy ◽  
Coronary Syndrome ◽  
Percutaneous Coronary ◽  
Hemorrhagic Complications

Abstract Background Prevention of hemorrhagic complications has emerged as a priority in patients undergoing Percutaneous Coronary Intervention (PCI) in addition to suppressing thrombotic complications. This goal is challenging to achieve in diabetic Acute Coronary Syndrome (ACS) patients as Diabetes Mellitus (DM) itself is a prothrombotic state with more pronounced vascular injury response and have a worse outcome after PCI compared with non-diabetic patients. In patients with ACS, Bivalirudin has been shown to result in similar rates of composite ischemia as Heparin plus GPI (GP IIb /IIIa inhibitor), while significantly reducing major bleeding and has received class I recommendation for PCI by American College of Cardiology (ACC 2013). Whether Bivalirudin is safe and effective specially in diabetic ACS patients undergoing PCI, as compared with Heparin (UFH) monotherapy, is unknown. Purpose To determine and compare the incidence of in-hospital and 30-day hemorrhagic complications and major adverse cardiac events (MACEs) as evidence of safety and efficacy using Bivalirudin versus Heparin in diabetic ACS patients undergoing PCI. Methods 218 diabetic ACS patients (age&gt;18 years and ≤75 years) who underwent PCI from May 2018 to April 2019 at University Cardiac Centre, BSM Medical University, Dhaka, Bangladesh were randomly assigned to have UFH or Bivalirudin. Before the guide wire crossed the lesion, 111 patients in the UFH group received a bolus of 70–100 U/kg (targeted activated clotting time, ACT: 200–250 s). 107 patients in the Bivalirudin group received a loading dose of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg/h for up to 4 hours. Dual antiplatelet (DAPT) loading as Aspirin 300 mg plus P2Y12 inhibitors (Clopidogrel 600 mg or Prasugrel 60 mg or Ticagrelor 180 mg) was given in all patients before the procedure. The maintenance dose of DAPT was continued for at least one month and patients were followed telephonically up to 30 days. The outcome measures were in-hospital and 30-day hemorrhagic complications and MACEs [death, MI, target vessel revascularization (TVR) and stroke]. Results Patients treated with Bivalirudin compared with Heparin had a significantly lower in-hospital incidence of QMI (0% vs. 6%; p=0.03) and major bleeding (0% vs. 7%; p=0.02). However, the incidence of cardiac death, stent thrombosis, TVR were no differences between two groups (p&gt;0.05). There was only one NQMI in the Bivalirudin group as opposed to 8% in the Heparin group in 30 days following stenting (p=0.04). Conclusion In diabetic ACS patients undergoing PCI, Bivalirudin is safe and effective as it reduces immediate and short-term hemorrhagic complications as well as MACEs as compared with Heparin. FUNDunding Acknowledgement Type of funding sources: None.

scholarly journals Urinary Thromboxane Production in Diabetic and Non-Diabetic Patients of Acute Coronary Syndrome

2020 ◽  
Vol 12 (20) ◽  
pp. 08-14
Author(s):  
Sheetal Chauhan ◽  
Yeshwanth Rao Karkala ◽  
Ajit Singh ◽  
Tom Devasia ◽  
Hashir Kareem ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Diabetic Patients ◽  
Coronary Syndrome ◽  
Thromboxane Production
Sign in / Sign up

Export Citation Format

Share Document